Whereas anti-PD1 inhibitors continue to improve outcomes in several subgroups of gastrointestinal tumours and in different indications, some drawback signals for immune checkpoint combination strategies, with anti-CTLA4 as an example, are now coming to light such as in the CheckMate 649 trial or in the INTEGA trial for instance. Here, CTLA4 is linked to digestive system neoplasm.